HYDERABAD, India — Teva Pharmaceutical Industries Ltd. and Dr. Reddy’s Laboratories (NYSE: RDY) announced the commercial launch of olanzapine tablets, an antipsychotic medication.
The companies said Tuesday that Teva’s olanzapine tablets in dosages of 2.5 mg, 5 mg, 7.5 mg, 10 mg and 15 mg and Dr. Reddy’s 20-mg olanzapine tablets have each been awarded a 180-day period of marketing exclusivity in the United States.
Dr. Reddy’s is supplying the 20-mg version of the product under an April 2011 commercialization, manufacture and supply pact with Teva. In addition, through the agreement, Dr. Reddy’s will launch its 2.5-mg, 5-mg, 7.5-mg, 10-mg, 15-mg and 20-mg olanzapine tablets upon the expiration of the 180-day exclusivity period.
Olanzapine is used to treat the symptoms of such conditions as schizophrenia and bipolar disorder.
According to Teva and Dr. Reddy’s, the products are a generic version of Eli Lilly’s Zyprexa. Annual U.S. sales of Zyprexa totaled approximately $3.2 billion as of September 2011, based on IMS Health sales data cited by Teva and Dr. Reddy’s.
